Recursion to Lay Off 20% of Workforce, Narrows Focus Amid Biotech Downturn

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

By Mariam Sunny (Reuters) -Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech industry downturn. Growing concerns over health policy under President Donald Trump’s administration have exacerbated existing challenges for the biotech industry, which has been struggling with decreased investor funding since t…

Avidity, FDA reach agreement on accelerated filing of rare disease drug

The news could further assuage industry concerns about the agency’s stance on rare disease therapies under a new administration.

Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the challenge of securing financing seen across the biopharma industry. Salt Lake City-based Recursion disclosed in a regulatory filing that it will incur about $11 million in charges tied to the workforce reduction this year, to consist of severance payments, …

Avidity to seek accelerated approval for FSHD drug; Axsome to run another trial

Plus, news about Mosanna Therapeutics, Concentra Biosciences, Elevation Oncology, Keros, TuHURA Biosciences and PolyPid: Avidity Biosciences says FDA is open to accelerated approval for FSHD drug: The RNA drug company

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

- Planning accelerated approval BLA submission in H2 2026, following topline data from